Close Menu

Agilent

For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 2019, beating the average Wall Street estimate of $1.4 billion.

News items for the in vitro diagnostics industry for the week of Nov. 16, 2020.

The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.

News items for in vitro diagnostics industry for the week of Sept. 14, 2020.

For the three months ended July 31,the firm's revenues contracted to $1.26 billion from $1.27 billion in Q3 2019, beating Wall Street analysts' average estimate of $1.21 billion.

The instrument is not as much of a turnkey solution as recent releases from Sciex and Thermo Fisher but marks a step in that direction for Agilent.

The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility. 

For the three months ended April 30, the firm's revenues were $1.24 billion, flat with $1.24 billion in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.

News items for the in vitro diagnostics industry for the week of May 18, 2020.

Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab. 

Pages